NCT05338307Active, not recruiting
Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention
Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
The aim of this study is to assess the feasibility of beta-hydroxybutyrate (BHB) supplementation in individuals who are undergoing a standard-of-care colonoscopy or flexible sigmoidoscopy.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 14 Apr 2022
- Start date
- 13 May 2022
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Colorectal cancer
- NCT number
- NCT05338307
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 13 May 2022 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior total proctocolectomy
- History of diabetes mellitus and are currently on medical diabetes therapy
- Cancer diagnosis where the subject is receiving active therapy
- Use of either a ketogenic diet or intermittent fasting (defined as a fasting period of 16 hours or more per day that is not associated with a medical procedure) during the 4 weeks prior to enrollment
Other illness
- History of inflammatory bowel disease
Lab values
- History of chronic kidney disease with an eGFR \< 60 mL/min/1.73m2
Age
- Subject is pregnant, a prisoner, or is under 18 years of age
Other
- Patient is not able to undergo colonoscopy or flexible sigmoidoscopy
Who the study is looking for
- Age of 18 years or older
- Scheduled for a colonoscopy or flexible sigmoidoscopy as part of the patient's standard care
- Can provide informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.